Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "RxSight"


3 mentions found


Analyst Young Li initiated coverage of the maker of ocular implants to resolve vision issues with a buy rating, citing its "unique" technology. "RXST makes the first and only post surgery adjustable intraocular lens to resolve cataracts. The differentiated and best in class tech enables premium [advanced technology intraocular lens] [total addressable expansion], and share taking, from 10% U.S. share to 50%+ U.S. [long term]," the analyst wrote. Checks suggest that nearly half of intraocular lens patients qualify, boosting the firm's confidence in modeling 45% LAL growth by the end of 2025 — ahead of consensus expectations. Jefferies' upside scenario would see share soaring nearly 80% to $90 per share and "assumes above expectations US market expansion of sIOL upgrades, as well as ATIOL share taking."
Persons: Jefferies, Young Li, RXST, Li Organizations: RxSight
Stock Chart Icon Stock chart icon U.S. Silica's year-to-date stock performance. Stock Chart Icon Stock chart icon Tetra Tech's year-to-date stock performance. Stock Chart Icon Stock chart icon RxSight's year-to-date stock performance. Stock Chart Icon Stock chart icon Praxis Precision Medicines' year-to-date stock performance. Stock Chart Icon Stock chart icon Getty's year-to-date stock performance.
Persons: they're Organizations: Tetra Tech, Medicines, Precision Medicines
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: You can't own U.S. Silica Holdings in this state, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: U.S. Silica Holdings, Tetra Tech, Rxsight and more.
Persons: Jim Cramer Organizations: Holdings, Tetra Tech
Total: 3